In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun Says Specialty Drug Spend Will Check Profit Growth

Executive Summary

Sun Pharmaceutical Industries has cautioned that investments to ramp up its specialty business will “check” profit growth near-term, as a one-off charge pushed down its fourth-quarter net income by more than 50%.

You may also be interested in...

Wait For Strategic Decisions Weighs Heavily On Mylan

With no news on the progress of a board-level strategic review on offer, investors reacted negatively to Mylan falling short of consensus sales figures. This took the firm's share price to its lowest level for more than five years.

Further US Lawsuit Claims Price-Fixing Conspiracy

Teva, along with Mylan, Pfizer, Sandoz and 16 other generics manufacturers, have found themselves in the spotlight after a further multi-state US lawsuit has accused them of participating in a price-fixing conspiracy.

Sun Pharma Commits To Generic Investment But Admits It Is Not Attractive In Current Environment

Sun’s MD Dilip Shanghvi made the rather frank admission during the firm’s third-quarter earnings call, maintaining that generics is nevertheless an “interesting” business for the Indian major. In light of this outlook, Sun has continued its policy of withdrawing what it feels are “unviable” ANDAs from under FDA review.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts